©1994 The Roger Wyburn-Mason and Jack
M. Blount Foundation for the Eradication of Rheumatoid Disease,
a.k.a. The Arthritis Trust of America®
Reprinted with permission
Our research started before the Roger Wyburn-Mason and Jack M. Blount
Foundation for Eradication of Rheumatoid Disease was chartered in
the State of Tennessee in 1982. Professor Roger Wyburn-Mason, MD,
PhD — author of several important medical textbooks and a
renown specialist in nerve diseases, honored by having two nerve
diseases named after him during his lifetime — along with
Vice Admiral Stamm — a world-class protozoologist —
came to the conclusion from their experimental work that a common
Limax amoeba was responsible for about 100 differently named collagen
tissue diseases, including rheumatoid arthritis, scleroderma, psoriasis,
and many other named diseases. All of these we now call "Rheumatoid
Wyburn-Mason and Stamm were probably wrong when identifying the
particular amoeba, Limax, for reasons our later research uncovered,
but the treatment protocol developed from Wyburn-Mason's hypothesis
— that an organism infecting all systems in the human body
for a person who has a genetic susceptibility for that organism
causes collagen tissue diseases — serendipitously determined
the very first medical treatment regimen to consistently and favorably
affect the progress of rheumatoid diseases. (See "The Roger
Wyburn-Mason MD, PhD Treatment for Rheumatoid Disease," http://www.arthritistrust.org.)
Thomas McPherson Brown, MD, of course, is owed a great deal for
his research in uncovering the probable role of mycoplasm in rheumatoid
disease, and also in developing a successful treatment.
From the 1970s onward, Professor Roger Wyburn-Mason experimented
with different chemicals that would cure rheumatoid arthritis and
related collagen tissue diseases. He developed the medical use of
copper solutions, bile, and other drugs that were not easy to take,
being somewhat toxic, but did have an effect on the disease, and
he finally settled on the use of clotrimazole, tinidazole, ornidizole,
nimorazole, allopurinol, rifampicin, potassium para amino benzoate,
Professor Roger Wyburn-Mason's research, summarized in 1976-1977,
was originally published under the title of The
Causation of Rheumatoid Disease and Many Human Cancers in
March 1978 in an expensive, limited hardcover edition in Japan and
then summarized in a Precis and Addenda, titled the same name as
his book by this foundation in 1983. (Both publications are available
through the Rheumatoid Disease Foundation, at "Books and Pamphlets,"
Robert Bingham, MD,
and Jack M. Blount, MD
Robert Bingham, MD, an orthopedic surgeon from California, who had
devoted his life to the problems of crippled children and, later,
crippled adults, visited Professor Roger Wyburn-Mason in England
and thereafter tried Wyburn-Mason's treatment with a great deal
of clinical success. He wrote up Wyburn-Mason's hypothesis in Orthopedic
Review and Modern Medicine,
an article that was subsequently read by Jack M. Blount, MD, a Philadelphia,
Mississippi physician who had had crippling rheumatoid arthritis
all of his adult life.
Dr. Blount was bed-ridden, drug- and alcohol-ridden, and no longer
practicing medicine because of the scourges of rheumatoid arthritis.
On reading Dr. Bingham's article, Dr. Blount tried to locate some
of the recommended drugs — especially Clotrimazole —
but no drug company would sell them to him in the United States
at that time. Jack Blount, therefore, on reading through the chemical
structure of many different drugs, discovered that Metronidazole
was related to Wyburn-Mason's Clotrimazole, Ornidazole, Nimorazole
and Tinidazole, a class of compounds called the 5-nitroimidazoles.
Dr. Blount got himself and some older patients well using Metronidazole
and thereafter reopened his medical clinic, where he became known
throughout the United States for treating and bringing great relief
— often permanent relief — to more than 17,000 patients,
including the Executive Director/Secretary of this Foundation. (See
"Rheumatoid Arthritis: Two Case Histories," http://www.arthritistrust.org.)
Later, Robert Bingham, MD, through his clinical work, added diiodohydroxyquinon
to the list of possibly effective medicines. Seldon Nelson, DO,
developed and was able to utilize resin-coated copper ions, which
was also added to our recommended treatment protocol. (See "The
Use of Ionic Copper in the Treatment of Arthritis," http://www.arthritistrust.org.)
The Rheumatoid Disease Foundation, a.k.a., The Arthritis Trust of
America, was founded by Branch Own Adkerson, MA, Frederick H. Binford,
MA, Robert Bingham, MD, Jack M. Blount, MD , Milas Brandon, MD,
Warren B. Causey, Perry A. Chapdelaine, Sr., MA, E. Harrison Clark,
PhD, Terry Crommelin, George Hay, HPA, Robert Kemp, Gus J. Prosch,
Jr., MD, Dr. Paul Pybus (South Africa: a surgeon and former student
of Roger Wyburn-Mason's), Carl J. Reich, MD, research pharmacologist
John R.A. Simoons, PhD, Don Vansant, Eugene S. Wolcott, MD, and
Roger Wyburn-Mason, MD, PhD.
As the treatment for various forms of collagen tissue diseases developed
by Roger Wyburn-Mason worked in a high percentage of cases —
as high as 80%, according to the records of some doctors, providing
the patient had not already had their immunological system ruined
by traditional treatments, in which case effectiveness dropped to
about 50% — this foundation and its medical advisory board
felt that more should be learned about amoebae. Toward that end,
Tony Chapdelaine, BA (now an MD, MSPH) volunteered to work without
charge for one year with one of the world's leading specialists
in certain types of amoebae, Robert Neff, PhD, of Vanderbilt University,
Tennessee. They were able to show the effect of different chemical
environments, particularly the effect of our recommended treatment
drugs, on amoebae in vitro (in the test tube).
When Tony Chapdelaine entered medical school, Dr. Neff assigned
a graduate student to finish the project, and Dr. Neff's final report
is titled Isolation and Cultivation of
Soil Amoebae from Fluids and Tissues of Patients with Rheumatoid
Disease, (see "Research: Isolation and Cultivation of
Soil Amoebae," "Research and Letters," http://arthritistrust.org.)
Vanderbilt University received a grant from us of $31,399.
Our medical advisor, Dr. Paul Pybus — based on Wyburn-Mason's
theory of the causation of joint pain in both rheumatoid arthritis
and osteoarthritis, as Wyburn-Mason had hypothesized some thirty
years earlier — developed a successful treatment procedure
which he titled "Intraneural Injections." This treatment,
for the first time, permits rheumatoid and osteoarthritis victims
to have relief from joint pain while undergoing other treatments,
without the use of harmful systemic cortisone. In many cases, Pybus's
treatment brought complete and permanent relief, especially for
arthritis-like pains and Osteoarthritis. Dr. Pybus prepared a booklet
entitled Intraneural Injections for Rheumatoid
Arthritis and Osteoarthritis, and Also The Control of Pain in Arthritis
of the Knee. This booklet was printed and is available to
physicians and the public through this foundation at "Pamphlets
and Books," http:www.arthritistrust.org.
Gus J. Prosch, Jr., MD, of Alabama became the first US physician
to learn and further develop Pybus's intraneural injections, and
this writer became the first one in the US to try the treatment,
with great success. Dr. Prosch contributed additionally to the development
of intraneural injections, teaching some 600 physicians in the proper
Rheumatoid Disease Foundation
Recommended Treatment Protocol
Gus J. Prosch, Jr., MD, and other physicians, such as Robert Johnson,
MD, of South Carolina, prepared formal medical treatment protocols
that are in use to this day. These treatment recommendations include
the importance and specifics of diet and vitamin and mineral supplements
in the treatment of various forms of arthritis, and both the medical
treatment protocol and diets and supplements were published by this
foundation and made available to the public and other physicians
and are found in our list of articles on this website. (See "The
Roger Wyburn-Mason Treatment for Rheumatoid Disease," http://www.arthritistrust.org.)
The work of Carl J. Reich, MD, on the importance of ionic calcium
deficiencies in arthritides was also included. (See "Calcium
and Vitamin D Deficiency," http://www.arthritistrust.org.)
Where indicated, simultaneous treatment for candidiasis and food
allergies was also added to the treatment protocol. Later, the importance
of mercury poisoning (tooth amalgams), improperly performed root
canal work, biodetoxification of intestinal tract and lipids (fatty
parts of cells), and other factors were seen as contributing "causes"
of rheumatoid diseases. (See "Biodetoxification and Food Allergies,"
"Candidiasis: Scourge of Arthritics," "On the Microbiology
of Peridontal Infections," "Root Canal Cover-Up Conceals
Numerous Side Effects," & "The World's Greatest Medical
The Rheumatoid Disease
Foundation's First National Medical Seminar: Public and Physicians
Three medical seminars were held by this foundation. The first was
held in 1985 in Birmingham, AL with a number of important speakers.
Gus J. Prosch, Jr., MD, and Dr. Paul K. Pybus not only taught other
physicians on the use of intraneural injections, but also held a
free medical clinic for the benefit of patient attendees and doctors.
These doctors were assisted in the clinic by Wilfred W. Mittelstadt,
DO, Seldon Nelson, DO, and Wyatt Simpson, MD.
In seminars, Garry F. Gordon, MD, discussed the controversial effects
of "Chelation Therapy on Circulatory Diseases and Arthritis."
Tony Chapdelaine, BA, discussed his work under Dr. Neff at Vanderbilt
University and presented a paper entitled "Preliminary Report
On Drug Research Involving Acanthamoeba and Naegleria."
Gus J. Prosch, Jr., MD, presented living demonstrations of amoeba
described by Tony Chapdelaine, BA, and Virginia Livingston-Wheeler,
MD, Progenitor cryptocides, using a dark field microscope.
Orville J. Davis, MD, presented the paper "Presently Accepted
Practices of Medicine that Have Not Been Proved."
Maureen Salaman presented "How to Survive in '85 (Freedom in
the Practice of Medicine)."
Kwang Jeon, PhD, biologist from University of Tennessee, Knoxville,
presented "Amoeba in Biomedical Research."
Ronald M. Davis, MD, presented "What I've Tried for Multiple
Sclerosis." Ronald Davis later was able to demonstrate a very
successful treatment for scleroderma and lupus erythematosus, which
this foundation now recommends. (See "Articles: Important"
tab at http://www.arthritistrust.org.)
William E. Catterall, DSc presented "Allergies and Their Modern
We also held a doctors' panel with questions fielded from both rheumatoid
disease patients as well as physicians in the audience.
Search for the Limax
Amoeba in Human Synovial Fluid
In one research program, referral physicians kindly took samples
of synovial fluid from the inflamed joints of patients and mailed
cartridges containing the fluid to two researchers. One was Robert
Neff, PhD, of Vanderbilt University, and the other was Kwang Jeon,
PhD, of University of Tennessee, Knoxville.
Kwang Jeon, for no charge to the Foundation, was able to demonstrate
that there were no live Limax amoebae in the synovial fluids, and
that further, the synovial cells "piled up and formed tissue-like
structures," and that the cells were "secreting collagen-like
He found that the cells that had been passed into new cultures many
times were multiplying normally after 12 months of in vitro culture,
which was a significant feature of itself, because other investigators
in the past had failed to obtain long-term cultures from synovial
effusions. Furthermore, their karyotype (specific characteristics)
exhibited no abnormalities.
Unfortunately we were unable to fund further work by Kwang Jeon,
PhD, although we would have liked to do so, considering his spectacular
results with synovial fluids submitted by many of our physicians.
at Bowman Gray School of Medicine and Laboratory Studies at Medical
College of Virginia
By that point, board members and consulting physicians had decided
that, funding permitted, we should tackle the research question
as to why Wyburn-Mason's treatment regimen worked when others did
not by three approaches:
- Double-blind studies on rheumatoid disease victims through a
reputable medical school, to determine the efficacy and safety
of one of our recommended drugs;
- To verify, if possible, Wyburn-Mason's and protozoologist Stamm's
apparent discovery that a common Limax amoeba was at the source
of causation of collagen tissue diseases;
- To determine, via in vitro tests and later simulated arthritic
rat tests, the biochemical behavior of the chosen drug, Clotrimazole.
Bowman Gray School of
Robert Turner, MD, of Bowman Gray School of Medicine, was chosen
to conduct double-blind studies on the use of Clotrimazole, with
a carefully screened group of rheumatoid arthritis patients, using
Clotrimazole and a placebo. To insure that the treatment protocol
would satisfy all scientific requirements, the Foundation had the
final research proposal reviewed by a professional biostatistician,
and, although we felt that there was one flaw in the study, Robert
Turner, MD, and his assisting physicians assured us this potential
problem would be handled properly. The flaw had to do with the Herxheimer
Effect, which all physicians knew would occur for those who were
favorably affected by Clotrimazole (or any of our other recommended
Based on studies performed by Dr. Paul K. Pybus, and his paper titled
The Herxheimer Effect, (http://www.arthritistrust.org)
we knew that the stronger the Herxheimer, the more likelihood of
wellness. One of Roger Wyburn-Mason's strong indications of a protozoal
causation for rheumatoid diseases was the fact that, whenever a
recommended drug was given, a strong Herxheimer often occurred,
which was interpreted to mean that toxins, or protein products of
newly killed protozoans, were affecting the patient by means of
a reaction similar to an antigen/antibody/allergenic effect inside
the human body, resulting in the outward manifestation of rheumatoid
arthritis and other rheumatoid diseases.
If the Herxheimer were to be interpreted by those physicians who
controlled the double-blind study as being caused by "toxicity"
of the Clotrimazole, then patients would be dropped from the study
prior to their achieving the wellness that had been observed in
many clinics by physicians who had already tried our treatment regimen.
Our research director, Dr. Simoons, and the Foundation's Executive
Director both in conference with Robert Turner, MD, and his associates
were assured that this factor would be properly compensated for
in the final study. Dr. Pybus made an additional trip from South
Africa to Bowman Gray School of Medicine to gain further reassurance
from Dr. Turner. Dr. Simoons, Dr. Pybus, Dr. Prosch, and the Foundation's
Executive Director all placed their concerns in writing, and all
were reassured again.
However, on completion of the study, and after expenditure of $137,750,
we discovered that Dr. Turner had permitted all of those who had
a Herxheimer effect to drop out, based on the presumption that the
Clotrimazole's "toxicity" was affecting the patient. It
became clear at the end that physicians who controlled the double-blind
study did not concern themselves with the Herxheimer, or, more likely,
placed little, if any, credence in its manifestation in the first
place, attributing all possible untoward effects to "toxicity."
(See June 1993 Newsletter, "The Bowman Gray School of Medicine
Clotrimazole Double-Blind Study," http://www.arthritistrust.org.)
In their favor, it might be said that the nature of double-blind
studies conducted under FDA auspices lends itself strongly to this
The result was that the study was totally inconclusive, in that
all of those trial patients who had a good chance of getting well
were dropped from the study and all of those who had a small probability
of getting well were permitted to stay in the study. This result
not only was in direct contradiction to earlier scientific studies,
but also in contradiction to all of our physicians' clinical experiences
( i.e., J.A. Wojtulewski, et. al. Clotrimazole in rheumatoid arthritis.
Ann Rheum Dis 39:469-472, 1980;
William Renforth, MD. Metronidazole cures rheumatoid arthritis,
originally published September 30, 1977, reprinted in Historical
Documents in Search of the Cure for Rheumatoid Disease, reprinted
by this Foundation in 1985; http://www.arthritistrust.org;
also see "Research and Letters," "Research"
Robert Turner, MD, submitted "Clotrimazole (C) Versus Placebo
(P) in Rheumatoid Arthritis (RA)" by William B. Dennison, Robert
A. Turner, June A. Johnson, Bradley Wells, to the American Rheumatism
Association for publication, where it was never published. (See
"Research and Letters," "Research" tab, http://www.arthritistrust.org.)
With additional hindsight, it is now felt that the "improvement"
criteria; i.e., the means of measuring and knowing when improvement
has occurred, was also faulty, it being based on traditional Non-Steroidal
Anti-Inflammatory (NSAID) comparison tests, rather than wellness-outcomes
Medical College of Virginia
While double-blind testing at Bowman Gray School of Medicine was
on-going, Brian M. Susskind, PhD, Assistant Professor, Surgery and
Microbiology and Immunology, and Richard C. Franson, PhD, Associate
Professor of Biochemistry, both of Medical College of Virginia,
were performing additional studies for this Foundation, an expenditure
to us totaling, $135,387.
Unlike the Bowman Gray School of Medicine research, where the double-blind
study was compromised by permitting those who had a chance of getting
well to drop out, all of the Medical College of Virginia studies
were laboratory-oriented and seemed to begin to explain the biochemical
basis to the use of Clotrimazole on human tissues. The study also
seemed to confirm our physicians' clinical experiences when using
any of the 5-nitroimidazoles on patients. (See "Research and
Letters," "Research" tab, http://www.arthritistrust.org.)
It is extremely unfortunate that we could not continue funding of
the research that was beginning to unravel the effect of Clotrimazole
on human biochemistry.
Can the Limax amoeba
As verification of the crux of Wyburn-Mason's hypothesis —
that an ordinary Limax amoeba, to which certain people were genetically
susceptible — was crucial to further research efforts, Susskind/Franson
undertook to duplicate Wyburn-Mason's work. They [Medical College
of Virginia researchers] were unable to validate the Wyburn-Mason/Stamm
findings. (Altogether, Medical College of Virginia received $135,387.)
(See "Research and Letters," "Research" tab,
Meanwhile, Dr. Paul K. Pybus and pathologist Davies of South Africa
worked together, at no salary, to search for Limax amoeba in synovial
fluid shipped to them by our physicians. This foundation funded
$4,497 for laboratory supplies and equipment.
Pybus and Davies were also unable to locate the Wyburn-Mason/Stamm
amoeba, but were able to identify macrophages in the synovial fluids,
and they were able to keep these macrophages alive for an extended
period of time. (See "Research and Letters," "Research"
Observe Pleomorphic Organisms in Rheumatoid Disease?
Based on Pybus' summary of all of our research work, two of us (Tony
Chapdelaine and this writer) visited with Lida Mattman, PhD, at
Wayne University. Dr. Lida Mattman was one of the world's leading
specialists in cell wall deficient forms. (See the 3rd edition of
her Cell Wall Deficient Forms, published
by the Chemical Rubber Company.)
We also received data and advice from Philip Paul Hoekstra, Sr.
and his son, Philip Paul Hoekstra, III, PhD. It was through review
of Mattman's work that some of us came to the conclusion that Wyburn-Mason/Stamm
had created cell wall deficient forms in minced meats by use of
antibiotics and thereafter had wrongly identified clusters of cell-wall
deficient bacteria as the Limax amoeba. Nonetheless, Wyburn-Mason
had correctly (or serendipitously) derived the world's first consistently
effective treatment, favorably affecting the majority of those afflicted
with rheumatoid arthritis.
In their defense, knowledge of cell wall deficient forms, or pleomorphic
organisms, was not widely spread when they performed their experiments,
nor was the knowledge widely dispersed on how antibiotics strip
off the walls of bacteria. Indeed, to this day, a trained protozoologist
can easily make similar mistakes, and obviously, most of the today's
medical profession is still unaware that they are not necessarily
destroying infective bacteria, through the liberal use of antibiotics,
but rather, in most cases, simply stripping off bacteria cell-walls
so that the bacteria can no longer be recognized by our immunological
system. (It is the cell wall of the bacteria that permits our defense
system to recognize an enemy.) Then, later, when the pleomorphic
form reconstructs itself, the physician will report that, "You
are infected again!"
While a negative can never be proven — that is, it would be
impossible to disprove Roger Wyburn-Mason/Stamm's hypothesis, but
only possible to establish high probability of its truth —
we now had good reason to believe that pleomorphic organisms are
at the root source of one of the causations of most forms of debilitating
diseases, including rheumatoid diseases, which encompass all of
the collagen tissue diseases. Changes in the environment surrounding
microorganisms influence their form and function, thus creating
health or disease states, accordingly. Known for more than 100 years,
and by modern microbiologists, this pristine truth has yet to trickle
through to the medical practitioner.
This foundation now accepts the fact that most degenerative diseases,
including rheumatoid arthritis, is a multi-factorial problem. We
mean that many factors operate to create the condition, such as
nutrition, candidiasis, stress, microorganisms, allergies, food
sensitivities, chemical sensitivities, hormonal unbalance, mercury
poisoning (tooth amalgams), faulty root canal surgery, foci of infection,
genetics, and so on. And some of these interacting factors may be
mimicking arthritis symptoms, rather than the pathology of the presumed
disease, itself. Clear-cut cases of candidiasis have been interpreted
by rheumatologists as "rheumatoid arthritis," and mis-treated
So, while we have planned — but remain unfunded — perhaps
$40,000,000 worth of meaningful research to accomplish in the future,
we also have to utilize the presently known and appropriate scientific
methodology capable of untangling the interrelated factors if we're
to help arthritics with satisfactory explanations.
The Second National
On July 1, 1986, in Santa Monica, California, we held our Second
National Medical Seminar, once again inviting both physicians and
victims of disease. Our then Chairman, John M. Baron, DO, monitored
the talks, and, as we did the year before, we also held a medical
clinic for demonstrating and using Dr. Paul K. Pybus's intraneural
injections, Gus J. Prosch, Jr. being the lead physician under the
auspices of Laszlo I. Belenyessy, MD.
Gus J. Prosch, Jr., MD, presented his paper on "Anti-amoebic
Treatment for Rheumatoid Disease."
Seldon Nelson, DO, talked on "Specifics of Treating Commensal
and Parasitic Problems."
Robert Bingham, MD, talked on "Nutritional Requirements for
Recovery from Arthritis."
George Yosef, MD, PhD, talked on "The Economics of Medical
Wayne Martin, BS. presented "Knowledge is a Hard-Bought Thing."
Luc De Schepper, MD, PhD, CA, talked on "Arthritis and Acupuncture."
Kay Hitchen, who then operated our English foundation, talked on
Helmut Christ, MD, ChB, talked on "Psoriasis Under Control
at Last — A New Alternative Treatment," and he also presented
a paper on the use of "Ozone Therapy" for various chronic
Dr. Christ's Psoriasis paper was accepted as a new foundation-recommended
protocol for treatment of psoriasis, as he was getting superior
results with hundreds of patients, claiming zero failures in controlling
the manifestations of psoriasis. (See "The Surprising Psoriasis
David R. Soll, PhD, talked on "Two Newly Discovered Switching
Systems in Candidas albicans and their Possible Role in Pathogenicity."
This paper was the first time that physicians knew of six switching
mechanisms by Candida albicans, plus a cell-wall deficient form,
as described by Phil Hoekstra, III, PhD — seven (7) survival
forms in all! (See "Candidiasis: Scourge of Arthritics,"
Since Candidiasis, like food allergies and chemical sensitivities,
has such a major impact on arthritides, a major paper was prepared
for distribution on the subject by this foundation.
Dr. Paul K. Pybus, MD, F.R.C.S., D.R.C.O.G., talked on the "Status
of Rheumatoid Disease Foundation Research" and also "On
the Herxheimer." Dr. Pybus' paper on the Herxheimer effect
is available through this foundation. (See "The Herxheimer
Luke Bucci, PhD, discussed "Co-Enzyme Q10: Review of Clinical
Uses With Emphasis on the Immune System." Later, Luke Bucci
summarized discussions of many physicians on their dietary requirements
for those afflicted with osteoarthritis, which led to this Foundation's
paper on "Prevention and Treatment of Osteoarthritis."
His summary also included the first recommendations for use of chondroitin
sulfate and glucosamine sulfate when treating arthritis. Later double-blind
studies by independent agencies confirmed Bucci's recommendations,
and these two substance are now sold for arthritic relief throughout
the United States, indeed, the world.
Phil Hoekstra, III, PhD, talked on "Scientific Effectiveness
of EDTA Therapy in Peripheral Collateral Arterial Circulation,"
a retrospective study that showed conclusively that EDTA therapy
solved 80% of the peripheral circulation problems.
Chelation therapy has since become an important adjunctive therapy
as recommended by The Rheumatoid Disease Foundation, the Foundation
also having prepared a paper on the subject.( See "Chelation
John T. Hicks, MD, talked on "Anti-Microbial Therapies in Rheumatoid
Arthritis: Past, Present, Future."
Robert F. Cathcart III, MD, talked on his research in "Vitamin
C in the Treatment of Infections and Immune Disorders," where
he described the bowel tolerance technique of determining the proper
amount of vitamin C to take for any given disease condition.
Dr. Cathcart's paper is published by the Foundation, and also serves
to supplement our overall arthritis regimen. (See "Vitamin
C: The Great Missing Vitamin," http://www.arthritistrust.org.)
Pat Connolly from the Price-Pottenger Nutrition Foundation talked
on "Nutrition From an Historical Perspective."
William Rea, MD, discussed "Environmental Aspects of Rheumatoid
Arthritis and Vascular Disease," his work, and the works of
earlier physicians, also serves as a basis for describing some of
the interacting problems of rheumatoid arthritis and other arthritides.
Zane R. Gard, MD, discussed his medical modification of L. Ron Hubbard's
sauna detoxification system under the title of "Toxic Bio-Accumulation
and Effective Detoxification." This form of detoxification
was also accepted by this foundation as one of the important puzzle-pieces
in describing the etiology of arthritides, that is, in decreasing
the storage of pesticides, herbicides and the like in the fatty
parts (lipids) of the cells. (See "Biodetoxification and Allergies,"
Dr. M. Be'ly talked on "The Differential Diagnosis of Osteoarthritis,
Qualitative Bone Changes Caused by Fluoride Investigated by Polarization
Optic Methods and Polarization Optic Methods in Osteoarthrology."
Fluoride, of course, is one of those governmentally approved poisons
that lowers abilities of the immune system and contributes to arthritic
diseases. (See "Arthritis" http://www.arthritistrust.org.)
The Rheumatoid Disease
Under the sponsorship of this Foundation, and at the Second National
Medical Seminar, Robert Bingham, MD, founded The Rheumatoid Disease
Medical Association, which also published The
Journal of The Rheumatoid Disease Medical Association.Within
a few months, this association became independent of the Foundation.
Robert Bingham, MD, went on to publish a series of small pamphlets
containing many thought-provoking articles on the treatment of arthritides.
At Robert Bingham's death, all rights not held elsewhere to publication
of the Journal's articles have reverted
to this foundation. The Journal's
articles are available on this website. (See "Books and Pamphlets,"
Our Second National Medical Seminar had many more physicians and
patients than the first convention, and, as such, it also cost the
Foundation about $30,000. However, the money was extremely well
spent, as the outcomes from the seminar, as with the first seminar,
stimulated useful papers, useful research, books, and successful
Ronald Davis, MD, for example, may have solved the treatment problem
of scleroderma and lupus erythematosus, his paper also now available
through this foundation. (See "Systemic Lupus Erythematosus
and Progressive Systemic Sclerosis" http://www.arthritistrust.org.)
All of the important subjects covered in both medical seminars have
found their place in educational materials that the Foundation has
for many years provided to those who inquire.
At very low donation-requested price — or free in many cases
of need — Foundation publications are being read around the
world. Most of the Foundation's publications have also been reprinted,
with our permission, in either Townsend
Letter for Doctors and Patients (now Townsend
Letter), a leading alternative medicine journal for doctors,
or in several instances, Explore for The Professional, also intended
for alternative practitioners. A website (http://www.arthritistrust.org)
has been established, making all papers and a physician referral
list available to everyone, worldwide, without charge.
In addition to Roger Wyburn-Mason's 350-page book, Causation
of Rheumatoid Disease and Many Human Cancers, and his Precis',
and Pybus' booklets on Intraneural
Injections available on our website, four books have also
been printed as well as published on the Internet by this foundation,
telling folks how to get well from arthritis and various forms of
rheumatoid disease. Many professional books and publications, as
well as links to our website, quote our foundation as a resource
for both physician referrals and information. Additionally, we recommend
several books from outside sources that appear to have an important
bearing on arthritis.
The Arthritis Trust
We established a new corporate presence in Canada as The Arthritis
Trust of Canada, but, as of this printing, we were unable to find
a director willing to handle this project without funding, and so
all queries from Canada were referred to the United States Office.
Without adequate funding and help, we reluctantly closed down this
new non-profit corporation, but not before providing all the libraries
in Ontario with alternative medical books, including some of our
Rheumatoid Disease Foundation
Trust of South Africa
The Rheumatoid Disease Foundation of South Africa was established
in 1983 by Dr. Paul Pybus, then our Chief Medical Advisor. It had
been led by Lucy Birnie. Alma Gouws later became Executive Director,
and with her unavailability, the foundation was determined to be
Arthritis and Rheumatism
Natural Therapy Research Association of England
Arthritis and Rheumatism Natural Therapy Research Association of
England was founded and headed by Rex E. Newnham, DO, ND, PhD, Cracoe
House Cottage, Cracoe, Nr. Skipton, North Yorkshire BD236LB.
The Arthritis Trust
The Arthritis Trust of California was established by this foundation
in 1997 at the request of Lyme disease/psoriasis sufferer J.D. Allen.
A branch office, unlike the national office, had as its chief function
to collect donations for the purpose of helping those who cannot
afford the cost of receiving the various treatments we now recognize
as important in achieving wellness. This branch office is inactive.
We welcome inquiries to establish regional branch offices in every
part of the United States. (We do not fund these branches, and they
must become self-sufficient, under our charter and by-laws.)
(In Lieu of Appropriate Funding)
This foundation has also cooperated with several other groups in
providing assistance for legitimate research, such as The Arthritis
Help Centers, as well as individual exploration of promising modalities.
Over a period of time, using various clinics, physicians were able
to demonstrate a link between certain common peppers used in cooking
or canned foods that stimulate arthritic pain in sensitive people.
The Arthritis Help Centers publishes a manual demonstrating their
findings for lay use. (See "Foods Found to Cause Pain, Swelling
and Stiffness," http://www.arthritistrust.org.)
We will be constantly exploring alternative means for solving the
disease problems of arthritics, and related diseases. Obviously,
if major funding were available, we would again fund appropriate
double-blind studies to establish the worth, or lack thereof, of
various treatment recommendations. Meanwhile, we constantly recommend
that disease victims read all of our articles before they choose
a physician, especially the article "How To Get Well,"
found under the tab of the same name on our website. Most likely,
no one physician or dentist will be trained to handle all of the
treatments that arthritic victims may need to explore. For that
reason, we list physicians and dentists on our webpage, (Physician
along with the kind of treatments they are willing to use. This
same physician listing is also available from us via US Postal Services.
Throughout 2001-2007 we have investigated and/or supported research
in immune milk and frequency resonance therapy. (See "Universal
Oral Vaccine," and John Myers under "Research" tab,
When Robert J. Coughlin of Pennsylvania bequeathed a sizeable amount
of money to the Foundation, our board determined to use it to develop
a medical clinic dedicated to bringing together under one roof all
of the treatments one should explore. Toward that end, $400,000
was used to purchase land directly in front of Fairview, Tennessee's
new city hall. On this land, it is our intent to build a small shopping
center and to use profits to establish the medical clinic. Whether
the lending agency ($2,300,000) benefits more than needful patients
remains to be learned.
and Sweepstake Programs
We principally employ direct-mail solicitation in the United States.
These mailings include up to 160,000 donor/members, as well as solicitation
for new donor/members interested in arthritis. To keep cost of finding
new donor/members to a minimum, we employ sweepstake programs. These
prizes may change from time to time. All of the sweepstakes programs
are operated by independent agencies. We also employ a telephone
solicitor in some states.
Added in 2001 is Vehicle Donation Program with the Vehicle Donation
Processing Center, Inc. of Monrovia, California. Any kind of automobile,
truck (running or not), boat, RV, trailer, lots, real estate, etc.,
from any part of the United States, can be donated to this foundation.
Our website has a link to this program, making it easy for a person
or company to donate. "Fair market value" is provided
according to appropriate IRS regulations.
On July 14, 2007, we held our third seminar with the following speakers:
Perry A. Chapdelaine, Sr., MA, presented "Is Arthritis Curable?"
challenging the present failed "politically correct" arthritis
treatment program, describing some of the foundation's history and
also successful treatments.
Curt Maxwell, alternative medical practitioner, presented "Modern
Medicine versus the Cult of Traditional Medicine," challenging
the modern medical paradigm.
Perry A. Chapdelaine, Jr., MD, MSPH: "A Clinical Approach to
Arthritis," which described the present nature of physician
"cookbook" medicine, and the strictures placed on the
physician by medical insurance.
Denise Chambul, BA, C.N.C: "Bio-Energetic Testing," demonstrating
the use of Electro Dermal Screening with a computer-based instrument.
Luby Chambul, DC: "Applied Kinesiology," demonstrating
how the testing of the strength of various muscles in the body can
help make medical diagnosis.
Our website also has been provided with links to other interesting
sites, physicians, and excellent alternative medical publications.
Thirty thousand newsletters have been mailed quarterly to all those
who have donated $15 or more to this foundation. Past issues are
now available on our website. These newsletters contain information
related to successful treatments about arthritis, and other related
stories. The last newsletter to be published was Fall of 2007, as
the Internet has created a new and more efficient communication
and Foundation Communications
Names of physicians for referral have grown from five physicians
in 1982, to more than 200 in 16 different countries (but mainly
the US), and the list seems to stay rather constant. Physicians
are free to sign up through our website, http://www.arthritistrust.org.
Although the Foundation has mailed out millions of solicitation
requests to potential donors since 1982, the Foundation has also
answered from two to ten personal letters per day since its founding
in 1982. At one count, during one year, more than 40,000 actions
(answered mail and telephone calls, physician referral lists, etc.)
Most impressive, however, is the mailing of free physician lists
to every person who orders books or articles, or simply calls on
the telephone, or who uses our homepage e-mail. The quantity of
four-page physician lists mailed out numbers in the tens of thousands
and increases annually. The physician list is now most easily available
on our website ("Physician Referral," http://www.arthritistrust.org.)
Copyright 1994 All rights reserved by The
Roger Wyburn-Mason and Jack M. Blount Foundation for the Eradication
of Rheumatoid Disease, a.k.a., The Arthritis Trust of America®,
7376 Walker Road, Fairview, Tennessee 37062